March 23, 2023 7:35am

Maybe, if stabilization begins without dramatic rises in share pricing; when and then, it will be “eaten” by electronic trading

Pre-open Indications: 6 Positive and 1 Negative Indications

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are UP +0.29% or (+93 points), S&P futures are UP +0.56% or (+22 point) and NASDAQ futures are UP +0.98% or (+124 points) early in the pre-open – so far

U.S. equity futures were higher early on Thursday,

Europe markets fall as investors weigh Fed rate hike; Bank of England decision due,

Asia-Pacific markets were mixed

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday, indexes floated down after waiting for Jerome and his policy decision; the Dow closed DOWN -530.49 points (-1.63%), the S&P closed DOWN -65.90 points (-1.65%) while the Nasdaq closed DOWN -190.15 points (-1.60%

Economic Data Docket: weekly jobless claims update at 8:30 a.m. ET and new home sales data

 

Wednesday’s (3/22) … RegMed Investors’ (RMi) closing bell: “more push and pull-down share pricings. A daily choice between keeping the focus on inflation and stemming the banking chaos while the cell and gene therapy sector collides with economics.” … https://www.regmedinvestors.com/articles/12884

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 26 of 35 (my coverage group)

 

Ebb and flow:

Q1/23 –

March – 5 positive and 11 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Wednesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         BioLife Solutions (BLFS) closed down -$1.09 after Tuesday’s +$1.29 with a negative -$0.61 or -2.61% aftermarket indication

Positive Indications:

Wednesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Beam Therapeutics (BEAM) closed down -$1.73 with a positive +$0.82 or +2.67% pre-open indication

·         Verve Therapeutics (VERV) closed down -$1.47 after Tuesday’s +$0.34 with a positive +$0.28 or +1.84% pre-open indication,

·         Sage Therapeutics (SAGE) closed down -$1.26 after Tuesday’s -$0.69 with a positive +$0.47 or +1.12% aftermarket indication

·         CRISPR Therapeutics (CRSP) closed down -$1.52 after Tuesday’s +$0.60 with a positive +$0.50 or +2.62% pre-open indication.

·         Intellia Therapeutics (NTLA) closed down -$2.64 with a positive +$0.53 or +1.43% pre-open indication

·         Ultragenyx (RARE) closed down -$1.06 with a positive +$0.34 or +0.91% aftermarket indication,

 

The BOTTOM LINE: I try to keep it simple and short!

Cell and gene therapy sector equities were significant losers Wednesday, tumbling pre and post Powell's comments.

Caution is expected as to “our” universe continues to feel shockwaves from the collapse of Silicon Valley Bank (SVB) as it will be months before the Fed releases $2 billion in deposits to control of its re-incorporated SVB Bridge entity.

Also, the rush of Q4 and FY22 earnings to release is STILL on … I do NOT believe there are not a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4 and FY22) are reported – any breakout is a false hope with the inevitable downside re-occurring.

·         26 of my 35 covered have reported - 9 remaining

·         There are more coming – waiting for announcements

·         Brainstorm Cell Therapeutics (BCLI) 3/30 - Thursday

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, I am mostly EARLY!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.